Tildrakizumab drug survival: can we really attribute the benefit to male sex?
Abstract
We read with considerable interest the recent retrospective, multicentre international study published in Clinical and Experimental Dermatology that reports 36-month drug survival rates for tildrakizumab in 517 adult patients with plaque psoriasis. These data add valuable real-world insights to the interleukin-23 inhibitor evidence base and support the long-term utility of tildrakizumab in routine clinical practice; however, two key methodological considerations merit further scrutiny.
Fields of Study & Subjects
Psoriasis: Treatment and Pathogenesis
Dermatology and Skin Diseases
Spondyloarthritis Studies and Treatments
Publication details
- Journal / source
- Clinical and Experimental Dermatology
- Volume
- 51
- Issue
- 6
- Pages
- 1129–1130
- Publication date
- 28 January 2026
- Language
- EN